Concepedia

Sustained inhibition of experimental neointimal hyperplasia with a genetically modified herpes simplex virus1 1Competition of interest: none.

Michael A. Curi, Christopher L. Skelly, Shari L. Meyerson, Zachary K. Baldwin, Viji Balasubramanian, Sunil J. Advani, Seymour Glagov, Bernard Roizman, Ralph R. Weichselbaum, Lewis B. Schwartz

Journal of Vascular Surgery · 2003 · 10 citations · 29 references

DOIFull text

Open access

Concepts

References

29

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

Robert L. Martuza, Amy Malick, James M. Markert et al. · Science · 1991 · 1K citations

, , +14

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

James M. Markert, Michael D. Medlock, Samuel D. Rabkin et al. · Gene Therapy · 2000 · 978 citations

, , +9

Mapping of Herpes Simplex Virus-1 Neurovirulence to γ <sub>1</sub> 34.5, a Gene Nonessential for Growth in Culture

J Chou, Earl R. Kern, Richard J. Whitley et al. · Science · 1990 · 711 citations

, , +9

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

R Rampling, G. Cruickshank, Vakis Papanastassiou et al. · Gene Therapy · 2000 · 598 citations

, , +10

Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty.

M W Chang, Emily Barr, Min Lü et al. · Journal of Clinical Investigation · 1995 · 356 citations · Full text

, , +13